Spero Therapeutics has appointed Debra Jeske Zack as Chief Medical Officer. The clinical-stage biopharmaceutical company said the move strengthens its clinical leadership team as it advances SP001, a Phase 2-ready third-generation anti-CD40L antibody being developed for IgG4-related disease and other immune-mediated conditions. Zack brings more than 25 years of experience in developing therapies for immune-mediated diseases, most recently serving as Chief Medical Officer of Exagen Inc. and previously holding clinical leadership roles at Xencor Inc. and Novartis' Biotherapeutics Development Unit. Spero Therapeutics shares were up nearly 2% in pre-market trading after closing at $1.19.
Spero Therapeutics IncAppointment of new CMO strengthens clinical leadership, advancing pipeline.
